Zimmer Biomet Holdings, Inc.

Zimmer Biomet Holdings, Inc.

ZBH

$97.35

Updated: 03/11/2026, 06:14:55

Market Cap
$18.57B
Sector
Healthcare
Industry
Medical - Devices
Country
US

No historical data available

Company Profile

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

USD
NYSE
CEO: Ivan Tornos
Employees: 17,000
https://www.zimmerbiomet.com
Asset Summaries
Latest generated summaries for ZBH

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
ZBH-10-k-fy2025.html6.6 MBtext/htmlENFiled 20/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 59 KPI observations

Revenue

8.2B

FY 2025 · Reported

Net income

0.7B

FY 2025 · Reported

Gross margin

69.7%

FY 2025 · Calculated

Free cash flow

1.5B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

0.5B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Product families and key brands

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureUnited States: 0.1% of reported revenueNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

Revenue exposure by reported geography
FY 2025 share of total net sales. Regional segments are kept as regions rather than falsely allocated to individual countries.
United States
+57.9%
United States
+0.1%

How the business makes money

Company overview

Global orthopedic medtech company founded 1927, spun off 2001, acquired Biomet 2015

99%
Source evidence
“We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (“CMFT”) products; bone cement; surgical products; and a suite of integrated digital and robotic technologies”

Instruments deployed to surgeons as long-lived assets

Hand-held surgical instruments are capitalized in PP&E, depreciated over ~5 years based on product life cycles, with depreciation recognized as SG&A

93%
Source evidence
“Instruments are hand-held devices used by surgeons during total joint replacement and other surgical procedures. Instruments are recognized as long-lived assets and are included in property, plant and equipment.”

Operating segments: Americas, EMEA, Asia Pacific

Three regional operating segments: Americas (principally U.S.), EMEA (principally Europe), Asia Pacific (principally Japan, China, Australia)

98%
Source evidence
“Our Americas operating segment is comprised principally of the U.S. and includes other North, Central and South American markets.”

Operating segments

Americas, EMEA, Asia Pacific operating segments

98%
Source evidence
“We allocate resources to achieve our operating profit goals through three regional operating segments. Our operating segments are comprised of the Americas; Europe, Middle East and Africa (“EMEA”); and Asia Pacific.”

Sales channels and consignment mix

Consignment sales ~85% of 2025 net sales; two principal channels

97%
Source evidence
“Consignment sales represented approximately 85 percent of our net sales in 2025.”

Product families and key brands

Knees, Hips, S.E.T., Technology & Data/Bone Cement/Surgical with ROSA robot and ZBEdge platform

97%
Source evidence
“Through our Technology & Data, Bone Cement and Surgical product category, we market a collective suite of our products and technologies as the ZBEdge® Platform.”

Net sales by geography (2025/2024/2023)

US $4,764.0M; International $3,467.5M; Total $8,231.5M in 2025, +7.2%

99%
Source evidence
“United States $ 4,764.0 $ 4,439.0 $ 4,288.8 7.3 % International 3,467.5 3,239.6 3,105.4 7.0 Total $ 8,231.5 $ 7,678.6 $ 7,394.2 7.2”

Segment assets as of December 31, 2025 and 2024 (in millions)

Segment Assets: Americas $1,440.0/$1,344.0; EMEA $737.0/$655.0; Asia Pacific $460.0/$311.0 (2025/2024)

95%
Source evidence
“Americas $ 160.2 $ 150.3 $ 134.5 $ 1,440.0 $ 1,344.0”

Net sales by product category (2025/2024/2023)

Knees $3,322.3M; Hips $2,093.5M; S.E.T. $2,150.2M; Technology & Data, Bone Cement and Surgical $665.6M in 2025

99%
Source evidence
“Knees $ 3,322.3 $ 3,173.5 $ 3,038.4 4.7 % Hips 2,093.5 1,999.1 1,967.2 4.7 S.E.T. 2,150.2 1,865.7 1,752.6 15.2 Technology & Data, Bone Cement and Surgical 665.6 640.3 636.0 4.0”

Net sales by segment 2025/2024/2023 (in millions)

Net sales: Americas $5,144.6/$4,794.8/$4,624.1; EMEA $1,828.8/$1,691.1/$1,592.4; Asia Pacific $1,258.1/$1,192.8/$1,177.7; Total $8,231.5/$7,678.6/$7,394.2 (2025/2024/2023)

97%
Source evidence
“Net Sales $ 5,144.6 $ 4,794.8 $ 4,624.1 $ 1,828.8 $ 1,691.1 $ 1,592.4 $ 1,258.1 $ 1,192.8 $ 1,177.7 $ 8,231.5 $ 7,678.6 $ 7,394.2”

Positioning and strategy

Paragon 28 acquisition

Paragon 28 acquired April 21, 2025; +2.5pp to 2025 net sales growth

98%
Source evidence
“Paragon 28 had a positive impact on our net sales growth of 2.5 percent in 2025.”

Monogram Technologies acquisition

Monogram Technologies acquired October 7, 2025

95%
Source evidence
“the acquisition of Monogram Technologies Inc. (“Monogram”) on October 7, 2025, including acquisition-related costs and higher interest expense incurred for debt borrowed for the acquisitions”

Market growth drivers and pricing pressure

Volume/mix +6.4% in 2025; aging population drives market growth; persistent pricing pressure

96%
Source evidence
“Market growth is being driven by an aging and active population, technological advancements, and data showcasing positive clinical outcomes, among other factors.”

R&D footprint and priorities

~2,000 R&D employees; R&D centers in 7 locations; AI/ML exploration

96%
Source evidence
“As of December 31, 2025, we employed approximately 2,000 research and development employees worldwide.”

Risks, financing, and outlook

2025 cost and earnings pressures

~$170M inventory/instrument charges, U.S. tariffs, acquisition costs, inflation pressured 2025 earnings

96%
Source evidence
“inventory and instrument charges of approximately $170 million related to certain product lines we intend to discontinue; costs related to the acquisition of Paragon 28”

Interest expense, net 2025/2024/2023 (in millions)

Interest expense, net: $292.8 (2025), $218.0 (2024), $201.2 (2023)

94%
Source evidence
“Interest expense, net 292.8 218.0 201.2”

2026 outlook

2026 net sales growth guidance of 2.5%-4.5%; operating profit expected to increase

97%
Source evidence
“We expect year-over-year net sales growth of 2.5 percent to 4.5 percent in 2026”

Material exposure graph

United States
Revenue Exposure

Americas segment, principally the U.S., is the largest revenue and profit contributor ($5,144.6M of $8,231.5M net sales in 2025).

Relevance 85·Dependency 80·Confidence 95
Source evidence
“Our Americas operating segment is comprised principally of the U.S. and includes other North, Central and South American markets.”
aging and active population
Demand Driver

Market growth driven by aging/active population, technological advancements and clinical outcome data

Relevance 80·Dependency 70·Confidence 94
Source evidence
“Market growth is being driven by an aging and active population, technological advancements, and data showcasing positive clinical outcomes, among other factors.”
consignment sales
Customer Exposure

Consignment model dominates distribution (~85% of 2025 net sales); company retains title to inventory until use in surgical procedures

Relevance 75·Dependency 80·Confidence 95
Source evidence
“Consignment sales represented approximately 85 percent of our net sales in 2025.”
government healthcare cost containment
Demand Driver

Government-sponsored healthcare budgets and hospital/health-system cost containment create pricing pressure in EMEA, Asia Pacific and most countries

Relevance 70·Dependency 60·Confidence 93
Source evidence
“The majority of countries in which we operate continue to experience pricing pressure from local hospitals, health systems, and governmental healthcare cost containment efforts.”
tariffs
Cost Driver

U.S. tariffs increased cost of products sold and contributed to 2025 net earnings decline

Relevance 70·Dependency 55·Confidence 94
Source evidence
“The increase in amount was primarily due to a higher volume of net sales, excess and obsolete inventory charges on certain products we intend to discontinue by 2032, U.S. tariffs and Paragon 28 inventory sold being stepped-up to fair value on the acquisition date.”
foreign currency exchange rates
Currency Exposure

FX changes added +0.8% to 2025 sales and expected +0.5% positive impact on 2026 growth; +1.8pp to International growth

Relevance 65·Dependency 55·Confidence 93
Source evidence
“our net sales experienced a positive effect of 0.8 percent from changes in foreign currency exchange rates in 2025”
Japan
Revenue Exposure

Japan is the largest Asia Pacific market, ~50% of the region's net sales in 2025

Relevance 60·Dependency 50·Confidence 95
Source evidence
“Japan is the largest market within this segment, accounting for approximately 50 percent of the region’s net sales in 2025.”
artificial intelligence
Demand Driver

Company leverages AI/data analytics in digital and robotic technologies and is exploring AI and machine learning applications as a core innovation strategy

Relevance 60·Dependency 50·Confidence 90
Source evidence
“We are broadening our offerings in certain of our product categories and exploring new technologies, including artificial intelligence and machine learning, with possible applications in multiple areas.”
Japan
Revenue Exposure

Japan is a principal market of the Asia Pacific segment ($1,258.1M net sales in 2025).

Relevance 60·Dependency 50·Confidence 90
Source evidence
“Our Asia Pacific operating segment is comprised principally of Japan, China and Australia and includes other Asian and Pacific markets.”
China
Revenue Exposure

China is a principal market of the Asia Pacific segment.

Relevance 55·Dependency 45·Confidence 90
Source evidence
“Our Asia Pacific operating segment is comprised principally of Japan, China and Australia and includes other Asian and Pacific markets.”
Zimmer Biomet Holdings, Inc.
Legal Exposure

Contingent consideration from M&A is remeasured to fair value each period with significant judgment; changes in milestone probability or revenue estimates could materially affect reported results.

Relevance 55·Dependency 40·Confidence 90
Source evidence
“The assumptions related to estimating the fair value of contingent consideration include a significant amount of judgment, and any changes in the underlying estimates could have a material impact on the amount of contingent consideration recorded in any given period.”
Zimmer Biomet Holdings, Inc.
Tax Exposure

Operating globally exposes the company to numerous complex tax regimes, affecting deferred tax valuation allowance judgments and effective tax rate.

Relevance 50·Dependency 40·Confidence 85
Source evidence
“We operate on a global basis and are subject to numerous and complex tax laws and regulations.”
Full company information
Latest profile, trading, valuation, and identifier data stored for ZBH.
Share price
$97.35
Market cap
$18.57B
Exchange
NYSE
Currency
USD
CEO
Ivan Tornos
Employees
17,000
IPO date
25/07/2001
Beta
0.485
Last dividend
$0.00
Day range
$94.50 – $97.35
52-week range
$79.12 – $103.70
1-day performance
2.99%
1-year performance
23.04%
Current drawdown (1Y)
-6.12%
CIK
0001136869
CUSIP
98956P102
ISIN
US98956P1021
Created
07/12/2025, 15:13:22
Last update
03/11/2026, 06:14:55

Track Zimmer Biomet Holdings, Inc. with an AI analyst

See which prediction-market events move ZBH, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to ZBH from your Railway `news_articles` table.

Zimmer Biomet Holdings, Inc. (ZBH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 08/06/2026, 19:08:30

Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026

PRNewsWire • STOCK • 22/05/2026, 18:30:00

Zimmer Biomet Holdings, Inc. (ZBH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 13/05/2026, 17:31:06

Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock

Zacks Investment Research • STOCK • 01/05/2026, 12:40:38

Zimmer Biomet Holdings, Inc. (ZBH) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 28/04/2026, 16:11:44

Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates

Zacks Investment Research • STOCK • 28/04/2026, 10:41:09

Zimmer Biomet Announces First Quarter 2026 Financial Results

PRNewsWire • STOCK • 28/04/2026, 08:30:00

Here's How Zimmer Biomet Is Placed Ahead of Q1 Earnings

Zacks Investment Research • STOCK • 20/04/2026, 11:35:47

Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2026 Financial Results

PRNewsWire • STOCK • 09/04/2026, 09:30:00

Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer

PRNewsWire • STOCK • 07/04/2026, 09:30:00

Is Zimmer Biomet Stock the Right Pick for Your Portfolio Now?

Zacks Investment Research • STOCK • 25/03/2026, 10:25:25

Zimmer Biomet Downgraded by BTIG on Limited Near-Term Upside

Market Data • Market Data • 23/03/2026, 16:43:57